Dialysis Corporation of America 

(Public, NASDAQ:DCAI)   Watch this stock   
Find more results for DCAI
Nov 5, 2009
Q3 2009 Earnings Conference Call
Nov 4, 2009
Q3 2009 Earnings Release
More events from AOL Finance »    

Key stats and ratios

Q3 (Sep '09) 2008
Net profit margin 5.41% 4.93%
Operating margin 7.91% 7.13%
EBITD margin - 10.34%
Return on average assets 8.09% 6.80%
Return on average equity 10.24% 8.46%
Employees 550 -

Address

1302 Concourse Drive Suite 204
Linthicum, MD 21090
United States - Map
+1-410-6940500 (Phone)
+1-410-6940596 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Dialysis Corporation of America discussed on blogs

Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 20, 2009

Dialysis Corporation of America discussions

  View all discussions »

Description

Dialysis Corporation of America develops and operates outpatient kidney dialysis centers that provide dialysis and ancillary services to patients suffering from chronic kidney failure, generally referred to as end stage renal disease (ESRD). It also provides acute inpatient dialysis treatments in hospitals, homecare services and dialysis centre management services. As of December 31, 2008, the Company owned 37 outpatient dialysis facilities in Georgia, Maryland, New Jersey, Pennsylvania, Ohio, Virginia and South Carolina. These dialysis facilities have a total designed capacity of 573 licensed stations. Of the 37 dialysis facilities, 33 are owned by the Company through subsidiaries: 23 wholly owned subsidiaries, one of which owns two facilities, and 13 majority owned subsidiaries in conjunction with the medical directors of those centres who hold minority interests. During the year ended December 31, 2008, the Company acquired two dialysis centres, one in Georgia and Maryland.

Officers and directors

Thomas K. Langbein
Chairman of the Board
Age: 63
Bio & Compensation - Reuters
Stephen W. Everett
President, Chief Executive Officer, Director
Age: 52
Bio & Compensation - Reuters
Andrew J. Jeanneret
Chief Financial Officer, Vice President - Finance
Age: 44
Bio & Compensation - Reuters
Daniel R. Ouzts
Vice President - Finance, Treasurer
Age: 62
Bio & Compensation - Reuters
Thomas P. Carey
Vice President - Operations
Age: 55
Bio & Compensation - Reuters
Joanne Zimmerman
Vice President - Clinical Services, Compliance Officer
Age: 54
Bio & Compensation - Reuters
Robert W. Trause
Director
Age: 66
Bio & Compensation - Reuters
Peter D. Fischbein
Director
Age: 69
Bio & Compensation - Reuters